Tiger Brokers

BUZZ-Alphamab hits 22-month peak as regulator accepts cancer drug application

Reuters
Sep 12
BUZZ-Alphamab hits 22-month peak as regulator accepts cancer drug application

** Alphamab Oncology 9966.HK jumps 15.2% to HK$12.1, highest since November 2023

** Stock set for biggest one-day pct gain since May 21

** Alphamab says new drug application for KN026 combined with chemotherapy to treat patients with metastatic gastric or gastroesophageal junction cancer accepted by China's National Medical Products Administration (NMPA)

** Adds KN026 co-developed with Shanghai JMT-Bio Technology - subsidiary of CSPC Pharmaceutical Group 1093.HK; multiple phase III clinical trials underway in China

** Shares of CSPC climb 4.2% to HK$10.54

** YTD, Alphamab shares surges 242.3%, CSPC stock soars 113.3%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10